In this study, we also demonstrated that pretreatment LAR was an independent prognostic factor affecting OS, PFS, and ORR in advanced NSCLC patients who received anti-PD-1 plus chemotherapy with or without antiangiogenic therapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.